{"id":1636,"date":"2026-06-26T15:31:21","date_gmt":"2026-06-26T14:31:21","guid":{"rendered":"http:\/\/seamlessbio.de\/?page_id=1636"},"modified":"2026-07-06T21:33:16","modified_gmt":"2026-07-06T20:33:16","slug":"dmpk-toxicology","status":"publish","type":"page","link":"https:\/\/seamlessbio.de\/de\/dmpk-toxicology\/","title":{"rendered":"Application DMPK &#038; Tox Studies"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"1636\" class=\"elementor elementor-1636\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ab56d3e e-con e-atomic-element e-flexbox-base e-c4797f5 \" data-id=\"ab56d3e\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"ab56d3e\">\n    \t\t<div class=\"elementor-element elementor-element-6af9889 elementor-widget elementor-widget-html\" data-id=\"6af9889\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<!-- YOAST SEO SETTINGS\nSlug:             applications\/dmpk-abc-transporter-assays\nFocus Keyword:    DMPK ABC transporter vesicle kit P-gp BCRP BSEP DDI FDA EMA Cell4Pharma\nSEO Title (EN):   DMPK & ABC Transporter Assays \u2014 Vesicle Kits FDA\/EMA DDI | SeamlessBio\nMeta Desc (EN):   ABC transporter vesicle kits for DMPK and DDI studies. BSEP, BCRP, P-gp, MRP1\u20135, MRP8. FDA 2020 DDI Guidance and EMA 2012 DDI Guideline compliant. 100 reactions\/kit. Cell4Pharma by SeamlessBio.\n-->\n<section class=\"sb-app\">\n<style>\n.sb-app,.sb-app *,.sb-app *::before,.sb-app *::after{box-sizing:border-box;}\n.sb-app{background:#fff;padding:70px 40px 90px;font-family:Arial,sans-serif;color:#202020;}\n.sb-app .wrap{max-width:1200px;width:100%;margin:0 auto;}\n.sb-app .bc{display:flex;flex-wrap:wrap;gap:8px;margin:0 0 24px;color:#777;font-size:14px;}\n.sb-app .bc a{color:#18b7b2!important;text-decoration:none!important;font-weight:700;}\n.sb-app .bc strong{color:#111;font-weight:800;}\n.sb-app .hero{padding:64px 56px;margin-bottom:48px;border-radius:30px;background:linear-gradient(135deg,#18b7b2 0%,#65d3cf 52%,#e9fbfa 100%);color:#fff;}\n.sb-app .hero .ey{display:inline-block;margin-bottom:14px;font-size:13px;font-weight:900;text-transform:uppercase;letter-spacing:1.8px;}\n.sb-app .hero h1{margin:0 0 18px;color:#fff;font-size:clamp(26px,3.2vw,40px);line-height:1.1;font-weight:900;letter-spacing:-1px;max-width:840px;}\n.sb-app .hero .sub{max-width:720px;margin:0 0 30px;color:#fff;font-size:17px;line-height:1.65;}\n.sb-app .hbtns{display:flex;flex-wrap:wrap;gap:14px;}\n.sb-app .btn1{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;background:#18b7b2;color:#fff!important;text-decoration:none!important;text-transform:uppercase;font-size:13px;font-weight:900;transition:all .25s;}\n.sb-app .btn1:hover{background:#139b97;transform:translateY(-2px);}\n.sb-app .btn2{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;background:transparent;border:2px solid #fff;color:#fff!important;text-decoration:none!important;text-transform:uppercase;font-size:13px;font-weight:900;transition:all .25s;}\n.sb-app .btn2:hover{background:#fff;color:#139b97!important;transform:translateY(-2px);}\n.sb-app .note{background:rgba(24,183,178,.08);border-left:4px solid #18b7b2;border-radius:8px;padding:18px 22px;margin-bottom:32px;font-size:14px;color:#444;line-height:1.7;}\n.sb-app .note strong{color:#111;display:block;margin-bottom:6px;font-size:15px;}\n\/* panels *\/\n.sb-app .panels{display:grid;grid-template-columns:repeat(3,1fr);gap:18px;margin-bottom:48px;}\n.sb-app .panel{border-radius:20px;padding:26px;border:1.5px solid rgba(24,183,178,.2);background:#f7fbfb;}\n.sb-app .panel.primary{border-color:#18b7b2;background:rgba(24,183,178,.06);}\n.sb-app .panel-tag{font-size:10px;font-weight:900;letter-spacing:.12em;text-transform:uppercase;color:#18b7b2;margin-bottom:10px;}\n.sb-app .panel h3{font-size:16px;font-weight:900;color:#111;margin:0 0 8px;}\n.sb-app .panel p{font-size:13px;color:#555;line-height:1.6;margin:0 0 12px;}\n.sb-app .panel .kits{font-size:12px;font-weight:700;color:#18b7b2;}\n.sb-app .sec{margin-bottom:34px;padding:34px;border-radius:26px;background:#fff;border:1px solid #eee;}\n.sb-app .sec h2{margin:0 0 14px;color:#111;font-size:22px;font-weight:900;}\n.sb-app .sec p{margin:0 0 12px;color:#555;font-size:15px;line-height:1.7;}\n.sb-app .tw{overflow-x:auto;margin-top:16px;}\n.sb-app table{width:100%;border-collapse:collapse;font-size:13px;min-width:540px;}\n.sb-app thead th{background:#18b7b2;color:#fff;padding:11px 13px;text-align:left;font-weight:700;font-size:12px;}\n.sb-app tbody tr:nth-child(even){background:#f5fffe;}\n.sb-app tbody tr:hover{background:#e8f9f8;}\n.sb-app tbody td{padding:9px 13px;vertical-align:top;border-bottom:1px solid #e5e5e5;line-height:1.5;}\n.sb-app table a{color:#18b7b2;text-decoration:none;font-weight:600;}\n.sb-app .ok{color:#18b7b2;font-weight:700;}\n.sb-app .faq{margin-bottom:34px;padding:34px;border-radius:26px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);}\n.sb-app .faq h2{margin:0 0 20px;color:#111;font-size:22px;font-weight:900;}\n.sb-app .faq-item{border-bottom:1px solid #e0e0e0;padding:18px 0;}\n.sb-app .faq-item:last-child{border-bottom:none;padding-bottom:0;}\n.sb-app .faq-q{font-size:15px;font-weight:900;color:#111;margin-bottom:8px;}\n.sb-app .faq-a{font-size:14px;color:#555;line-height:1.7;}\n.sb-app .related{margin-bottom:34px;padding:28px 34px;border-radius:26px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);}\n.sb-app .related h3{margin:0 0 16px;color:#111;font-size:18px;font-weight:900;}\n.sb-app .rel-grid{display:grid;grid-template-columns:repeat(2,1fr);gap:12px;}\n.sb-app .rel-grid a{display:flex;align-items:center;min-height:50px;padding:12px 16px;border-radius:12px;background:#fff;border:1px solid #e0e0e0;color:#111!important;text-decoration:none!important;font-size:13px;font-weight:700;transition:all .2s;}\n.sb-app .rel-grid a:hover{border-color:#18b7b2;color:#139b97!important;}\n.sb-app .hub-back{text-align:center;padding:20px 0 0;border-top:1px solid rgba(24,183,178,.15);margin-bottom:16px;}\n.sb-app .hub-back a{color:#18b7b2;font-size:14px;font-weight:700;text-decoration:none;}\n.sb-app .cta{padding:54px 34px;border-radius:30px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);text-align:center;}\n.sb-app .cta h2{margin:0 0 12px;color:#111;font-size:28px;font-weight:900;}\n.sb-app .cta p{max-width:760px;margin:0 auto 26px;color:#555;font-size:15px;line-height:1.65;}\n.sb-app .ctabtns{display:flex;flex-wrap:wrap;gap:14px;justify-content:center;}\n.sb-app .ctab1,.sb-app .ctab2{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;font-size:13px;font-weight:900;text-transform:uppercase;text-decoration:none!important;transition:all .25s;}\n.sb-app .ctab1{background:#18b7b2;color:#fff!important;}\n.sb-app .ctab1:hover{background:#139b97;transform:translateY(-2px);}\n.sb-app .ctab2{background:transparent;border:2px solid #18b7b2;color:#18b7b2!important;}\n.sb-app .ctab2:hover{background:#18b7b2;color:#fff!important;transform:translateY(-2px);}\n@media(max-width:1100px){.sb-app .hero{padding:48px 36px;}.sb-app .panels{grid-template-columns:1fr;}.sb-app .rel-grid{grid-template-columns:1fr;}}\n@media(max-width:700px){.sb-app{padding:50px 16px 70px;}.sb-app .hero{padding:40px 24px;border-radius:24px;}.sb-app .hero h1{font-size:25px;}.sb-app .hbtns,.sb-app .ctabtns{flex-direction:column;}.sb-app .btn1,.sb-app .btn2,.sb-app .ctab1,.sb-app .ctab2{width:100%;}.sb-app .sec,.sb-app .faq{padding:20px;}.sb-app .cta{padding:36px 20px;}}\n<\/style>\n<div class=\"wrap\">\n  <div class=\"bc\">\n    <a href=\"http:\/\/seamlessbio.de\/\">Home<\/a><span>\/<\/span>\n    <a href=\"https:\/\/www.seamlessbio.de\/applications\/\">Applications<\/a><span>\/<\/span>\n    <strong>DMPK &amp; ABC Transporter Assays<\/strong>\n  <\/div>\n\n  <div class=\"hero\">\n    <span class=\"ey\">SeamlessBio \u00b7 Cell4Pharma \u00b7 FDA 2020 \u00b7 EMA 2012 \u00b7 ICH M12 \u00b7 DACH Exclusive<\/span>\n    <h1>DMPK &amp; ABC Transporter Assays \u2014 Vesicle Kits for FDA\/EMA DDI Studies<\/h1>\n    <p class=\"sub\">Drug metabolism and pharmacokinetics (DMPK) studies are mandatory for all new molecular entities (NMEs) before IND submission to the FDA or CTA submission to the EMA. SeamlessBio supplies the Cell4Pharma range of ABC transporter membrane vesicle kits \u2014 HEK293-derived inside-out vesicles, 100 reactions per kit, full activity validation per lot, FDA\/EMA DDI Guidance-compliant documentation.<\/p>\n    <div class=\"hbtns\">\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/dmpk-transporter-kit\/abc-transporter-vesicle-kits\" class=\"btn1\">View All Kits<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/about-us\/contact-imprint\/\" class=\"btn2\">Contact Us<\/a>\n    <\/div>\n  <\/div>\n\n  <div class=\"note\">\n    <strong>Regulatory requirement \u2014 FDA 2020 &amp; EMA 2012 DDI Guidance:<\/strong>\n    The FDA 2020 Drug Interaction Guidance and EMA 2012 DDI Guideline require evaluation of P-gp (ABCB1), BCRP (ABCG2), OATP1B1\/1B3, OCT1\/2, OAT1\/3, MATE1\/2K for all NMEs, and BSEP (ABCB11) for hepatotoxicity risk assessment. The membrane vesicle assay is the accepted in vitro method for BSEP, BCRP, P-gp, and MRP family transporters. ICH M12 (2023) harmonises FDA and EMA requirements.\n  <\/div>\n\n  <!-- 3 PANELS -->\n  <h2 style=\"font-size:22px;font-weight:900;color:#111;margin:0 0 20px;\">Recommended DDI Testing Panels<\/h2>\n  <div class=\"panels\">\n    <div class=\"panel primary\">\n      <div class=\"panel-tag\">IND-Enabling<\/div>\n      <h3>Minimal FDA DDI Panel<\/h3>\n      <p>Covers FDA mandatory transporters for BSEP (DILI), BCRP and P-gp (DDI). Minimum package for IND transporter section.<\/p>\n      <div class=\"kits\">BSEP + BCRP + P-gp + Control Vesicles<\/div>\n    <\/div>\n    <div class=\"panel\">\n      <div class=\"panel-tag\">DILI Risk Assessment<\/div>\n      <h3>DILI Risk Panel<\/h3>\n      <p>Complete hepatic transporter panel \u2014 dual\/triple liability assessment. Identifies DILI risk from compensatory pathway inhibition beyond BSEP alone.<\/p>\n      <div class=\"kits\">BSEP + MRP2 + MRP3 + MRP4 + Control<\/div>\n    <\/div>\n    <div class=\"panel\">\n      <div class=\"panel-tag\">Full Coverage<\/div>\n      <h3>Full DDI Panel<\/h3>\n      <p>Comprehensive transporter inhibition profile for NMEs with complex ADME or known hepatic\/renal metabolism. Supports complete IND DDI section.<\/p>\n      <div class=\"kits\">All 11 kits \u2014 complete transporter portfolio<\/div>\n    <\/div>\n  <\/div>\n\n  <!-- COMPLETE KIT TABLE -->\n  <div class=\"sec\">\n    <h2>Complete Cell4Pharma Vesicle Kit Portfolio<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Transporter<\/th><th>Gene<\/th><th>Location<\/th><th>Clinical Relevance<\/th><th>Kit<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><strong>BSEP<\/strong><\/td>\n            <td>ABCB11<\/td>\n            <td>Hepatocyte canalicular membrane<\/td>\n            <td>Drug-induced liver injury (DILI) \u2014 BSEP inhibition causes cholestatic hepatotoxicity. FDA mandatory for all NMEs.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/bsep-vesicle-kit\">BSEP Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>BCRP<\/strong><\/td>\n            <td>ABCG2<\/td>\n            <td>Intestine, liver, BBB, placenta<\/td>\n            <td>Oral bioavailability, CNS penetration, DDI with rosuvastatin, methotrexate, imatinib. FDA mandatory.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/bcrp-vesicle-kit\">BCRP Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>P-gp (MDR1)<\/strong><\/td>\n            <td>ABCB1<\/td>\n            <td>Intestine, liver, BBB, kidney, placenta<\/td>\n            <td>Most clinically significant efflux transporter \u2014 oral bioavailability, CNS exclusion, multi-drug resistance. FDA mandatory.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/pgp-vesicle-kit\">P-gp Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>P-gp \/ FluoPgp<\/strong><\/td>\n            <td>ABCB1<\/td>\n            <td>As P-gp above<\/td>\n            <td>Fluorescent substrate-based P-gp assay \u2014 higher throughput, no radiolabel required. Compatible with standard plate reader detection.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/pgp-fluopgp-vesicle-kit\">FluoPgp Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>MRP1<\/strong><\/td>\n            <td>ABCC1<\/td>\n            <td>Ubiquitous \u2014 basolateral liver, lung, kidney<\/td>\n            <td>GSH-conjugate and glucuronide efflux. Multidrug resistance in cancer. Basolateral hepatic efflux in DILI risk panel.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/mrp1-vesicle-kit\">MRP1 Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>MRP2<\/strong><\/td>\n            <td>ABCC2<\/td>\n            <td>Hepatocyte canalicular, intestine, kidney<\/td>\n            <td>Canalicular bile acid efflux \u2014 compensatory pathway when BSEP is inhibited. Dual BSEP\/MRP2 inhibition = higher DILI risk.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/mrp2-vesicle-kit\">MRP2 Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>MRP3<\/strong><\/td>\n            <td>ABCC3<\/td>\n            <td>Basolateral hepatocyte, intestine<\/td>\n            <td>Basolateral bile acid safety valve \u2014 upregulated when canalicular efflux is impaired. Key element of DILI dual liability panel.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/mrp3-vesicle-kit\">MRP3 Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>MRP4<\/strong><\/td>\n            <td>ABCC4<\/td>\n            <td>Hepatocyte, kidney, platelet<\/td>\n            <td>Bile acid renal compensation pathway. Alternative efflux when hepatic routes impaired. Platelet drug transport.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/mrp4-vesicle-kit\">MRP4 Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>MRP5<\/strong><\/td>\n            <td>ABCC5<\/td>\n            <td>Ubiquitous \u2014 brain, heart<\/td>\n            <td>Nucleotide and cyclic nucleotide efflux. CNS drug resistance. Cardiac drug accumulation risk.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/mrp5-vesicle-kit\">MRP5 Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>MRP8<\/strong><\/td>\n            <td>ABCC11<\/td>\n            <td>Liver, brain, breast tissue<\/td>\n            <td>Steroid and bile acid conjugate transport. Emerging role in oncology drug resistance.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/mrp8-vesicle-kit\">MRP8 Kit \u2192<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Control Vesicles<\/strong><\/td>\n            <td>Non-transfected HEK293<\/td>\n            <td>\u2014<\/td>\n            <td>Required for all vesicle assays \u2014 background correction for non-specific ATP-dependent uptake. Without this, IC\u2085\u2080 values are unreliable.<\/td>\n            <td><a href=\"https:\/\/shop.seamlessbio.de\/en\/products\/control-vesicle-kit\">Control Kit \u2192<\/a><\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- KIT SPECS -->\n  <div class=\"sec\">\n    <h2>Kit Specifications<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Parameter<\/th><th>Specification<\/th><\/tr><\/thead>\n        <tbody>\n          <tr><td><strong>Expression system<\/strong><\/td><td>HEK293 \u2014 inside-out membrane vesicles overexpressing human ABC transporter<\/td><\/tr>\n          <tr><td><strong>Reactions per kit<\/strong><\/td><td class=\"ok\">100 reactions<\/td><\/tr>\n          <tr><td><strong>Vesicle orientation<\/strong><\/td><td>Inside-out \u2014 ATP-dependent transport into vesicle lumen (correct orientation for transport assay)<\/td><\/tr>\n          <tr><td><strong>Substrates<\/strong><\/td><td>Radiolabelled or MS-detectable \u2014 taurocholic acid (BSEP), estradiol glucuronide (MRP2), methotrexate (MRP), vinblastine (P-gp)<\/td><\/tr>\n          <tr><td><strong>Lot validation<\/strong><\/td><td>IC\u2085\u2080 with reference inhibitor per lot \u2014 cyclosporin A (BSEP\/P-gp), Ko143 (BCRP), MK-571 (MRP)<\/td><\/tr>\n          <tr><td><strong>Documentation<\/strong><\/td><td>CoA with activity data, cell line documentation, lot-specific quality data. Available in German for EMA submissions.<\/td><\/tr>\n          <tr><td><strong>Regulatory compliance<\/strong><\/td><td class=\"ok\">FDA 2020 DDI Guidance, EMA 2012 DDI Guideline, ICH M12 (2023)<\/td><\/tr>\n          <tr><td><strong>Storage<\/strong><\/td><td>\u221280\u00b0C | Avoid freeze-thaw cycles<\/td><\/tr>\n          <tr><td><strong>Delivery DACH<\/strong><\/td><td class=\"ok\">2\u20135 business days \u2014 EU stock in Passau. No US import delays.<\/td><\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- FAQ -->\n  <div class=\"faq\">\n    <h2>Frequently Asked Questions<\/h2>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Which transporters are mandatory for FDA IND submission?<\/div>\n      <div class=\"faq-a\">The FDA 2020 Drug Interaction Guidance requires evaluation of P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, and MATE2K for all NMEs. BSEP evaluation is recommended for all NMEs as part of hepatotoxicity risk assessment. The membrane vesicle assay is the accepted method for P-gp, BCRP, BSEP, and MRP family transporters. EMA 2012 DDI Guideline requirements are broadly harmonised with the FDA list via ICH M12 (2023).<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Why is the Control Vesicle Kit required for every assay?<\/div>\n      <div class=\"faq-a\">Control vesicles from non-transfected HEK293 cells are essential for background correction in all vesicle assays. They measure non-specific ATP-dependent uptake and passive substrate accumulation without the transporter of interest. ATP-dependent transport = (signal in transporter vesicles) \u2212 (signal in control vesicles). Without this subtraction, IC\u2085\u2080 values are unreliable and non-compliant with FDA\/EMA guidance. Each Cell4Pharma vesicle kit assay protocol specifies control vesicle use.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">What is the dual liability concept for DILI risk assessment?<\/div>\n      <div class=\"faq-a\">BSEP inhibition alone is necessary but not always sufficient to predict clinical DILI. Simultaneous inhibition of BSEP and MRP2 or MRP3 impairs both the primary canalicular bile acid efflux pathway and the compensatory basolateral safety valve \u2014 dramatically increasing intracellular bile acid accumulation and hepatotoxicity risk. Testing the complete BSEP\/MRP2\/MRP3\/MRP4 panel provides a more accurate DILI risk profile than BSEP alone, and is increasingly expected by FDA reviewers during IND review.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">What is the difference between the P-gp and P-gp FluoPgp kit?<\/div>\n      <div class=\"faq-a\">The standard P-gp Vesicle Kit uses radiolabelled substrate (vinblastine) \u2014 accepted as the gold-standard method in regulatory submissions. The FluoPgp kit uses a fluorescent substrate that is compatible with standard plate reader detection without requiring radiochemistry infrastructure. Both kits give equivalent IC\u2085\u2080 values for reference inhibitors. For regulatory IND packages, either format is accepted by FDA and EMA when accompanied by the required QC data and reference inhibitor validation.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Why source Cell4Pharma kits from SeamlessBio DACH rather than US suppliers?<\/div>\n      <div class=\"faq-a\">Most vesicle kit suppliers are US-based \u2014 leading to 7\u201314 day transatlantic shipping, cold-chain risk, customs delays, and time-zone support gaps. Cell4Pharma kits via SeamlessBio ship from EU stock in Passau: 2\u20135 business days DACH, 3\u20137 days wider EU, same cold chain, no import documentation. For CRO and pharma teams working to IND timelines, this supply reliability difference is significant. German-language documentation available for EMA submissions.<\/div>\n    <\/div>\n  <\/div>\n\n  <div class=\"related\">\n    <h3>Related Applications &amp; Products<\/h3>\n    <div class=\"rel-grid\">\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/dmpk-transporter-kit\/abc-transporter-vesicle-kits\">\u2192 ABC Transporter Vesicle Kits \u2014 Full Portfolio<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/dmpk-transporter-kit\/abc-transporter-vesicle-kits\/human-bsep-vesicle-kits\">\u2192 Human BSEP Vesicle Kits<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/dmpk-transporter-kit\/drug-transporter-assay-service-ciptec\">\u2192 Drug Transporter Assay Service (Ciptec)<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/cro-contract-research\">\u2192 CRO &amp; Contract Research Supply Guide<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/fbs-for-pharma\">\u2192 FBS for Pharmaceutical Applications<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">\u2192 FBS Low Endotoxin \u22645 EU\/mL<\/a>\n    <\/div>\n  <\/div>\n  <div class=\"hub-back\"><a href=\"https:\/\/www.seamlessbio.de\/applications\/\">\u2190 All Application Guides Overview<\/a><\/div>\n  <div class=\"cta\">\n    <h2>Request Cell4Pharma Vesicle Kits &amp; DDI Study Design Support<\/h2>\n    <p>ABC transporter vesicle kits from EU stock \u2014 2\u20135 day DACH delivery. FDA 2020 \/ EMA 2012 \/ ICH M12 aligned documentation. Free consultation on which panel fits your IND programme.<br>Email: info@seamlessbio.de | +49 851 37932226<\/p>\n    <div class=\"ctabtns\">\n      <a href=\"mailto:info@seamlessbio.de\" class=\"ctab1\">Contact Us<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/dmpk-transporter-kit\/abc-transporter-vesicle-kits\" class=\"ctab2\">View Kits \u2192<\/a>\n    <\/div>\n  <\/div>\n<\/div>\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"FAQPage\",\n      \"@id\": \"https:\/\/www.seamlessbio.de\/applications\/dmpk-abc-transporter-assays#faqpage\",\n      \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Which transporters are mandatory for FDA IND submission?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"The FDA 2020 Drug Interaction Guidance requires evaluation of P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, and MATE2K for all NMEs. BSEP evaluation is recommended for all NMEs as part of hepatotoxicity risk assessment. The membrane vesicle assay is the accepted method for P-gp, BCRP, BSEP, and MRP family transporters. EMA 2012 DDI Guideline requirements are broadly harmonised with the FDA list via ICH M12 (2023).\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Why is the Control Vesicle Kit required for every assay?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Control vesicles from non-transfected HEK293 cells are essential for background correction in all vesicle assays. They measure non-specific ATP-dependent uptake and passive substrate accumulation without the transporter of interest. ATP-dependent transport = (signal in transporter vesicles) \u2212 (signal in control vesicles). Without this subtraction, IC\u2085\u2080 values are unreliable and non-compliant with FDA\/EMA guidance. Each Cell4Pharma vesicle kit assay protocol specifies control vesicle use.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the dual liability concept for DILI risk assessment?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"BSEP inhibition alone is necessary but not always sufficient to predict clinical DILI. Simultaneous inhibition of BSEP and MRP2 or MRP3 impairs both the primary canalicular bile acid efflux pathway and the compensatory basolateral safety valve \u2014 dramatically increasing intracellular bile acid accumulation and hepatotoxicity risk. Testing the complete BSEP\/MRP2\/MRP3\/MRP4 panel provides a more accurate DILI risk profile than BSEP alone, and is increasingly expected by FDA reviewers during IND review.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the difference between the P-gp and P-gp FluoPgp kit?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"The standard P-gp Vesicle Kit uses radiolabelled substrate (vinblastine) \u2014 accepted as the gold-standard method in regulatory submissions. The FluoPgp kit uses a fluorescent substrate that is compatible with standard plate reader detection without requiring radiochemistry infrastructure. Both kits give equivalent IC\u2085\u2080 values for reference inhibitors. For regulatory IND packages, either format is accepted by FDA and EMA when accompanied by the required QC data and reference inhibitor validation.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Why source Cell4Pharma kits from SeamlessBio DACH rather than US suppliers?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Most vesicle kit suppliers are US-based \u2014 leading to 7\u201314 day transatlantic shipping, cold-chain risk, customs delays, and time-zone support gaps. Cell4Pharma kits via SeamlessBio ship from EU stock in Passau: 2\u20135 business days DACH, 3\u20137 days wider EU, same cold chain, no import documentation. For CRO and pharma teams working to IND timelines, this supply reliability difference is significant. German-language documentation available for EMA submissions.\"\n      }\n    }\n      ]\n    },\n    {\n      \"@type\": \"BreadcrumbList\",\n      \"@id\": \"https:\/\/www.seamlessbio.de\/applications\/dmpk-abc-transporter-assays#breadcrumb\",\n      \"itemListElement\": [\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 1,\n          \"name\": \"Home\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/\"\n        },\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 2,\n          \"name\": \"Applications\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/applications\/\"\n        },\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 3,\n          \"name\": \"DMPK & ABC Transporter Assays\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/applications\/dmpk-abc-transporter-assays\"\n        }\n      ]\n    }\n  ]\n}\n<\/script>\n<\/section>\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Home\/ Applications\/ DMPK &amp; ABC Transporter Assays SeamlessBio \u00b7 Cell4Pharma \u00b7 FDA 2020 \u00b7 EMA 2012 \u00b7 ICH M12 \u00b7 DACH Exclusive DMPK &amp; ABC Transporter Assays \u2014 Vesicle Kits [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_eb_attr":"","footnotes":""},"class_list":["post-1636","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biologicals for DMPK &amp; Toxicology Studies | SeamlessBio<\/title>\n<meta name=\"description\" content=\"Cell4Pharma ABC transporter vesicle kits for FDA\/EMA-aligned DDI\/DILI studies. Full panel &amp; assay service.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/dmpk-toxicology\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biologicals for DMPK &amp; Toxicology Studies | SeamlessBio\" \/>\n<meta property=\"og:description\" content=\"Cell4Pharma ABC transporter vesicle kits for FDA\/EMA-aligned DDI\/DILI studies. Full panel &amp; assay service.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/dmpk-toxicology\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-06T20:33:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/dmpk-toxicology\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/dmpk-toxicology\\\/\",\"name\":\"Biologicals for DMPK & Toxicology Studies | SeamlessBio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-06-26T14:31:21+00:00\",\"dateModified\":\"2026-07-06T20:33:16+00:00\",\"description\":\"Cell4Pharma ABC transporter vesicle kits for FDA\\\/EMA-aligned DDI\\\/DILI studies. Full panel & assay service.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/dmpk-toxicology\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/dmpk-toxicology\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/dmpk-toxicology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Application DMPK &#038; Tox Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"width\":309,\"height\":88,\"caption\":\"SeamlessBio\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biologicals for DMPK & Toxicology Studies | SeamlessBio","description":"Cell4Pharma ABC transporter vesicle kits for FDA\/EMA-aligned DDI\/DILI studies. Full panel & assay service.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/dmpk-toxicology\/","og_locale":"de_DE","og_type":"article","og_title":"Biologicals for DMPK & Toxicology Studies | SeamlessBio","og_description":"Cell4Pharma ABC transporter vesicle kits for FDA\/EMA-aligned DDI\/DILI studies. Full panel & assay service.","og_url":"https:\/\/seamlessbio.de\/de\/dmpk-toxicology\/","og_site_name":"SeamlessBio","article_modified_time":"2026-07-06T20:33:16+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/dmpk-toxicology\/","url":"https:\/\/seamlessbio.de\/dmpk-toxicology\/","name":"Biologicals for DMPK & Toxicology Studies | SeamlessBio","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-06-26T14:31:21+00:00","dateModified":"2026-07-06T20:33:16+00:00","description":"Cell4Pharma ABC transporter vesicle kits for FDA\/EMA-aligned DDI\/DILI studies. Full panel & assay service.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/dmpk-toxicology\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/dmpk-toxicology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlessbio.de\/dmpk-toxicology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"Application DMPK &#038; Tox Studies"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","width":309,"height":88,"caption":"SeamlessBio"},"image":{"@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/1636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=1636"}],"version-history":[{"count":11,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/1636\/revisions"}],"predecessor-version":[{"id":1871,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/1636\/revisions\/1871"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=1636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}